A group of investors led a $29m Series B round in Galux.

A group of investors, including InterVest, an investment manager, PATHWAY Investment, a provider of private market solutions, Korea Development Bank, a wholly state-owned policy development bank, SL Investment, SneakPeek Investments, DAYLI Partners, NCORE Ventures, Yuanta Investment, venture capital firms, Korea Investment & Securities, an investment bank, and Mirae Asset Securities, South Korea’s largest investment banking and brokerage firm, led a $29m Series B round in Galux, a South Korea-based biotech pioneering AI-driven protein therapeutics design. Proceeds from this financing round will be used to further enhance its AI platform, expand R&D infrastructure, and accelerate preclinical validation of proprietary pipelines. Through these efforts, Galux aims to unlock new therapeutic opportunities and expand drug discovery into target classes that have historically been difficult to address using conventional approaches.